Imaging agents
View Patent ↗The present invention provides novel compounds that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging). The present invention also provides imaging compositions for use within nuclear medicine applications. Additionally, the present invention provides methods of imaging.
1. A composition comprising a radio-labeled compound, wherein said radio-labeled compound is selected from the group consisting of
[ 11 C](−)-β-hydroxyphenethylguanidine,
[ 11 C]para-methoxy-phenethylguanidine,
[ 11 C]meta-hydroxyphenethylguanidine,
[ 11 C]para-hydroxyphenethylguanidine,
[ 11 C]3,4dihydroxyphenethylguanidine,
N-[ 11 C]guanyl-meta-octopamine,
N-[ 11 C]guanyl-norepinephrine,
N-[ 11 C]guanyl-(−)-metaraminol,
[ 14 C](−)-β-hydroxyphenethylguanidine,
[ 14 C]para-methoxy-phenethylguanidine,
[ 14 C]meta-hydroxyphenethylguanidine,
[ 14 C]para-hydroxyphenethylguanidine,
[ 14 C]3,4-dihydroxyphenethylguanidine,
N-[ 14 C]guanyl-meta-octopamine,
N-[ 14 C]guanyl-norepinephrine,
N-[ 14 C]guanyl-(−)-metaraminol,
meta-[ 18 F]fluorophenethylguanidine,
para-[ 18 F]fluorophenethylguanidine,
ortho-[ 18 F]fluorophenethylguanidine,
para-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
ortho-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
para-hydroxy-meta-[ 123 I]iodo-phenethylguanidine,
para-hydroxy-meta-[ 124 I]iodo-phenethylguanidine, and
para-hydroxy-meta-[ 131 I]iodo-phenethylguanidine.
2. A radio-labeled compound comprising the following structure:
wherein said radio-labeled compound is selected from the group consisting of a [ 11 C] radio-labeled compound, a [ 14 C] radio-labeled compound, a [ 18 F] radio-labeled compound, a [ 211 At] radio-labeled compound, a [ 76 BR] radio-labeled compound, a [ 131 I] radio-labeled compound, a [ 124 I] radio-labeled compound, and a [ 123 I] radio-labeled compound, wherein R1, R2, R3, R4 and R5 are the same or different and are selected from the group consisting of H, halogen, hydroxyl, guanyl, methoxy, methyl, amino, and nitro, wherein R6 is selected from the group consisting of H and hydroxyl, wherein at least one of R2, R3, R4 and R6 is hydroxyl, and wherein R7 is H or CH 3 .
3. The compound of claim 2 , wherein said radio-labeled compound is selected from the group consisting of
[ 11 C](−)-β-hydroxyphenethylguanidine,
[ 11 C]meta-hydroxyphenethylguanidine,
[ 11 C]para-hydroxyphenethylguanidine,
[ 11 C]3,4-dihydroxyphenethylguanidine,
N-[ 11 C]guanyl-meta-octopamine,
N-[ 11 C]guanyl-norepinephrine,
N-[ 11 C]guanyl-(−)-metaraminol,
[ 14 C](−)-β-hydroxyphenethylguanidine,
[ 14 C]meta-hydroxyphenethylguanidine,
[ 14 C]para-hydroxyphenethylguanidine,
[ 14 C]3,4-dihydroxyphenethylguanidine,
N-[ 14 C]guanyl-meta-octopamine,
N-[ 14 C]guanyl-norepinephrine,
N-[ 11 C]guanyl-(−)-metaraminol,
para-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
ortho-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
para-hydroxy-meta-[ 123 I]iodo-phenethylguanidine,
para-hydroxy-meta-[ 124 I]iodo-phenethylguanidine, and
para-hydroxy-meta-[ 131 I]iodo-phenethylguanidine.
4. An imaging composition comprising the radio-labeled compound described in claim 2 .
5. A method of imaging an organ comprising:
(a) applying a composition to a subject, wherein said composition comprises a radio-labeled compound selected from the group consisting of:
1) a compound described by Formula A, wherein Formula A is represented by:
wherein said compound is selected from the group consisting of a [ 11 C] radio-labeled compound, a [ 18 F] radio-labeled compound, a [ 211 At] radio-labeled compound, a [ 76 BR] radio-labeled compound, a [ 131 I] radio-labeled compound, a [ 124 I] radio-labeled compound, and a [ 123 I] radio-labeled compound, wherein R1, R2, R3, R4 and R5 are the same or different and are selected from the group consisting of H, halogen, hydroxyl, guanyl, methoxy, methyl, amino, and nitro, wherein R6 is selected from the group consisting of H and hydroxyl, wherein at least one of R2, R3, R4 and R6 is hydroxyl, and wherein R7 is H or CH 3 ; and
2) a compound selected from the group consisting of:
[ 11 C](−)-β-hydroxyphenethylguanidine,
[ 11 C]para-methoxy-phenethylguanidine,
[ 11 C]meta-hydroxyphenethylguanidine,
[ 11 C]para-hydroxyphenethylguanidine,
[ 11 C]3,4-dihydroxyphenethylguanidine,
N-[ 11 C]guanyl-meta-octopamine,
N-[ 11 C]guanyl-norepinephrine,
N-[ 11 C]guanyl-(−)-metaraminol,
meta-[ 18 F]fluorophenethylguanidine,
para-[ 18 F]fluorophenethylguanidine,
ortho-[ 18 F]fluorophenethylguanidine,
para-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
ortho-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
para-hydroxy-meta-[ 123 I]iodo-phenethylguanidine,
para-hydroxy-meta-[ 124 I]iodo-phenethylguanidine, and
para-hydroxy-meta-[ 131 I]iodo-phenethylguanidine, and
(b) detecting gamma radiation emitted by said composition and forming an image therefrom.
6. The method of claim 5 , wherein said organ is selected from the group consisting of the heart, adrenal medulla, and tumors of the adrenal medulla.
7. The method of claim 5 , wherein said imaging is PET imaging.
8. The method of claim 5 , wherein said imaging is SPECT imaging.
9. The method of claim 5 , wherein said compound described by Formula A is selected from the group consisting of
[ 11 C](−)-β-hydroxyphenethylguanidine,
[ 11 C]meta-hydroxyphenethylguanidine,
[ 11 C]para-hydroxyphenethylguanidine,
[ 11 C]3,4-dihydroxyphenethylguanidine,
N-[ 11 C]guanyl-meta-octopamine,
N-[ 11 C]guanyl-norepinephrine,
N-[ 11 C]guanyl-(−)-metaraminol,
para-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
ortho-[ 18 F]fluoro-meta-hydroxy-phenethylguanidine,
para-hydroxy-meta-[ 123 I]iodo-phenethylguanidine
para-hydroxy-meta-[ 124 I]iodo-phenethylguanidine, and
para-hydroxy-meta-[ 131 I]iodo-phenethylguanidine.
10. An imaging composition comprising the radio-labeled compound described in claim 1 .
11. The method of claim 5 , wherein said imaging is obtained with a gamma camera.